VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy Volunteers

Authors
Category Primary study
JournalInvestigative ophthalmology & visual science
Year 2023
This article has no abstract
Epistemonikos ID: 16db6a57bd61d583ec2c0153735e04b7147394f0
First added on: Dec 07, 2023